Coronary artery diseasePredictive Value of Total Atrial Conduction Time Estimated With Tissue Doppler Imaging for the Development of New-Onset Atrial Fibrillation After Acute Myocardial Infarction
Section snippets
Methods
Beginning in February 2004, consecutive patients admitted with AMIs treated with primary percutaneous coronary intervention were included in an ongoing registry. All patients were treated according to the institutional AMI protocol. This protocol, designed to improve care around AMI, includes structured medical therapy and standardized follow-up at the outpatient clinic, as described previously.15 In addition, 2-dimensional echocardiography was performed <48 hours after admission. All patients
Results
A total of 726 patients were included. Nine patients (1.2%) died during hospitalization before echocardiographic assessment could be performed, and in 22 patients (3.0%), echocardiographic assessment was not available within 48 hours of admission for logistic reasons. An additional 35 patients (4.8%) were excluded because 1-year follow-up was not completed. From the remaining 660 patients, 47 patients were excluded with previous AF or AF during baseline echocardiography. The final patient
Discussion
The major findings of the present study can be summarized as follows. (1) The incidence of new-onset AF after AMI during mean follow-up of 21 months was 7%, despite optimal contemporary treatments. (2) After adjusting for the strongest clinical and echocardiographic predictors, moderate or severe mitral regurgitation, LA max, and PA-TDI duration were independent predictors of the development of new-onset AF in patients after AMI. (3) PA-TDI duration provided incremental value for the prediction
References (24)
- et al.
New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience
Am Heart J
(2000) - et al.
Clinical and prognostic significance of atrial fibrillation in acute myocardial infarction
Am J Cardiol
(1997) - et al.
Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation
Am J Cardiol
(2003) - et al.
Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience
J Am Coll Cardiol
(1997) - et al.
The signal-averaged P wave duration: a rapid and noninvasive marker of risk of atrial fibrillation
J Am Coll Cardiol
(1993) - et al.
Atrial activation time determined by transthoracic Doppler tissue imaging can be used as an estimate of the total duration of atrial electrical activation
J Am Soc Echocardiogr
(2005) - et al.
MISSION!: optimization of acute and chronic care for patients with acute myocardial infarction
Am Heart J
(2007) - et al.
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology
J Am Soc Echocardiogr
(2005) - et al.
Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography
J Am Soc Echocardiogr
(2003) - et al.
Comparison of usefulness of left ventricular diastolic versus systolic function as a predictor of outcome following primary percutaneous coronary angioplasty for acute myocardial infarction
Am J Cardiol
(2006)
Echocardiographic evaluation of left atrial size and function: current understanding, pathophysiologic correlates, and prognostic implications
Am Heart J
Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women
J Am Coll Cardiol
Cited by (0)
Dr. Schalij received grants from Biotronik, Berlin, Germany; Boston Scientific Corporation, Natick, Massachusetts; and Medtronic, Inc., Minneapolis, Minnesota. Dr. Bax received grants from Biotronik; BMS Medical Imaging, North Billerica, Massachusetts; Boston Scientific Corporation; Edwards Lifesciences, Irvine, California; GE Healthcare, Buckinghamshire, United Kingdom; Medtronic, Inc.; and St. Jude Medical, St. Paul, Minnesota.